January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
23 citations,
July 1993 in “Pharmacotherapy” Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.
20 citations,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
January 1983 in “Elsevier eBooks” Cyproterone acetate is used to treat conditions like prostate cancer, early puberty, excessive sexual drive, and female androgenization by affecting androgen functions and suppressing certain hormones.
January 2010 in “Yearbook of Endocrinology” Older men with lower levels of available testosterone are more likely to be frail.
25 citations,
May 2012 in “The Journal of Sexual Medicine” Finasteride reduces corpus cavernosum weight but doesn't affect erectile response in rats.
7 citations,
May 2015 in “General and Comparative Endocrinology” Finasteride negatively affects fish reproduction and gonadal development.
21 citations,
January 2020 in “General and Comparative Endocrinology” Lack or blocking of SRD5a, a key component in hormone creation, can lead to conditions like pseudohermaphrodism and affect hair growth, bone mass, muscle strength, and reproductive health. More research is needed on its regulation from fertilization to adulthood.
20 citations,
August 2010 in “The Journal of Urology” Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.
April 2005 in “The Journal of urology/The journal of urology” Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
3 citations,
January 2018 in “Reproduction, Fertility and Development” Birth control pills increase certain receptor activities in female gerbil prostate glands and can lead to prostate changes.
9 citations,
January 2018 in “Journal of the European Academy of Dermatology and Venereology” A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.
May 2017 in “Urology and andrology” Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.
6 citations,
May 2020 in “JAMA Ophthalmology” Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.
January 2019 in “Jui rinsho hifuka” A dog's hair loss was caused by a hormone-secreting testicular tumor.
57 citations,
January 1986 in “The Prostate” The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
28 citations,
January 2003 in “Urologic oncology” Suppressing certain hormones might help prevent prostate cancer.
23 citations,
July 2007 in “The journal of investigative dermatology/Journal of investigative dermatology” Hair follicle bulge cells don't help skin regrow after glucocorticoid damage; interfollicular epidermis cells do.
9 citations,
September 2014 in “Cancer Epidemiology, Biomarkers & Prevention” Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.
6 citations,
January 2010 in “Neoplasma” Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.
237 citations,
December 2001 in “Urology” Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
36 citations,
July 2014 in “Neuromuscular Disorders” A patient with a larger than usual genetic mutation had a broader range of symptoms for a muscle disease.
3 citations,
March 2005 in “The Journal of urology/The journal of urology” Dutasteride may help shrink prostate cancer tumors.
108 citations,
February 2008 in “The Journal of urology/The journal of urology” Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.
29 citations,
July 2009 in “BJU international” Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
17 citations,
July 2017 in “Molecular and Cellular Endocrinology” Effective treatments for spinal and bulbar muscular atrophy are not yet available; more research is needed.
48 citations,
June 2014 in “Neurobiology of Disease” The study suggests that motor neurons created from stem cells of patients with spinal and bulbar muscular atrophy show signs of the disease, including changes in protein levels and cell functions.
25 citations,
December 2008 in “The Journal of Urology” Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.
19 citations,
August 2014 in “Journal of Ethnopharmacology” The study created a test that found hormonal and toxic effects in plant and fungal extracts using prostate cancer cells.